MEMANTINE HYDROCHLORIDE (memantine) by Molecular Devices is 12. Approved for moderate to severe dementia of the alzheimer's type. First approved in 2018.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its…
Worked on MEMANTINE HYDROCHLORIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis